Cargando…

Ropinirole Cotreatment Prevents Perivascular Glial Recruitment in a Rat Model of L-DOPA-Induced Dyskinesia

Dopamine replacement therapy for Parkinson’s disease is achieved using L-DOPA or dopamine D2/3 agonists, such as ropinirole. Here, we compare the effects of L-DOPA and ropinirole, alone or in combination, on patterns of glial and microvascular reactivity in the striatum. Rats with unilateral 6-hydro...

Descripción completa

Detalles Bibliográficos
Autores principales:	Elabi, Osama F., Espa, Elena, Skovgård, Katrine, Fanni, Silvia, Cenci, Maria Angela
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10378233/ https://www.ncbi.nlm.nih.gov/pubmed/37508522 http://dx.doi.org/10.3390/cells12141859

Ejemplares similares

Distinctive Effects of D1 and D2 Receptor Agonists on Cortico-Basal Ganglia Oscillations in a Rodent Model of L-DOPA-Induced Dyskinesia
por: Skovgård, Katrine, et al.
Publicado: (2022)

On the neuronal circuitry mediating l-DOPA-induced dyskinesia
por: Cenci, M. Angela, et al.
Publicado: (2018)

Presynaptic Mechanisms of l-DOPA-Induced Dyskinesia: The Findings, the Debate, and the Therapeutic Implications
por: Cenci, M. Angela
Publicado: (2014)

The locus coeruleus Is Directly Implicated in L-DOPA-Induced Dyskinesia in Parkinsonian Rats: An Electrophysiological and Behavioural Study
por: Miguelez, Cristina, et al.
Publicado: (2011)

Opioid system in L-DOPA-induced dyskinesia
por: Pan, Jing, et al.
Publicado: (2017)

L-dopa-Dependent Effects of GLP-1R Agonists on the Survival of Dopaminergic Cells Transplanted into a Rat Model of Parkinson Disease
por: Elabi, Osama F., et al.
Publicado: (2021)

Cell type-specific plasticity of striatal projection neurons in parkinsonism and L-DOPA-induced dyskinesia
por: Fieblinger, Tim, et al.
Publicado: (2014)

Maladaptive Synaptic Plasticity in L-DOPA-Induced Dyskinesia
por: Wang, Qiang, et al.
Publicado: (2016)

Predictors of Levo-dopa induced Dyskinesias in Parkinson's Disease
por: Athulya, RT, et al.
Publicado: (2020)

Circuit Mechanisms of L-DOPA-Induced Dyskinesia (LID)
por: Yang, Kai, et al.
Publicado: (2021)

Corticostriatal Plastic Changes in Experimental L-DOPA-Induced Dyskinesia
por: Ghiglieri, Veronica, et al.
Publicado: (2012)

Propranolol Relieves L-Dopa-Induced Dyskinesia in Parkinsonian Mice
por: Shi, Ziqing, et al.
Publicado: (2020)

Pathophysiological Mechanisms and Experimental Pharmacotherapy for L-Dopa-Induced Dyskinesia
por: Fabbrini, Andrea, et al.
Publicado: (2021)

L-dopa-induced dyskinesia: beyond an excessive dopamine tone in the striatum
por: Porras, Gregory, et al.
Publicado: (2014)

Striatal Plasticity in L-DOPA- and Graft-Induced Dyskinesia; The Common Link?
por: Rylander Ottosson, Daniella, et al.
Publicado: (2016)

Inhaling xenon ameliorates l‐dopa‐induced dyskinesia in experimental parkinsonism
por: Baufreton, Jérôme, et al.
Publicado: (2018)

Involvement of the bed nucleus of the stria terminalis in L-Dopa induced dyskinesia
por: Bastide, Matthieu F., et al.
Publicado: (2017)

Ropinirole for the treatment of restless legs syndrome
por: Kushida, Clete A
Publicado: (2006)

Update on ropinirole in the treatment of Parkinson’s disease
por: Shill, Holly A, et al.
Publicado: (2009)

Spectrophotometric Estimation of Ropinirole Hydrochloride in Tablets
por: Shete, Yogita, et al.
Publicado: (2009)

Treatment of Gait Ignition Failure with Ropinirole
por: Cohen-Oram, Alexis N., et al.
Publicado: (2014)

Differential involvement of Ras-GRF1 and Ras-GRF2 in L-DOPA-induced dyskinesia
por: Bido, Simone, et al.
Publicado: (2015)

Imbalanced Dopaminergic Transmission Mediated by Serotonergic Neurons in L-DOPA-Induced Dyskinesia
por: Navailles, Sylvia, et al.
Publicado: (2012)

L-DOPA-Induced Dyskinesia in a Genetic Drosophila Model of Parkinson’s Disease
por: Blosser, Joshua A., et al.
Publicado: (2020)

The Vasomotor Response to Dopamine Is Altered in the Rat Model of l‐dopa‐Induced Dyskinesia
por: Booth, Samuel, et al.
Publicado: (2020)

Eltoprazine modulated gamma oscillations on ameliorating L‐dopa‐induced dyskinesia in rats
por: Bi, Yuewei, et al.
Publicado: (2023)

Mass spectrometry imaging identifies abnormally elevated brain l-DOPA levels and extrastriatal monoaminergic dysregulation in l-DOPA–induced dyskinesia
por: Fridjonsdottir, Elva, et al.
Publicado: (2021)

The Role of the Subthalamic Nucleus in L-DOPA Induced Dyskinesia in 6-Hydroxydopamine Lesioned Rats
por: Aristieta, Asier, et al.
Publicado: (2012)

Untangling Cortico-Striatal Connectivity and Cross-Frequency Coupling in L-DOPA-Induced Dyskinesia
por: Belić, Jovana J., et al.
Publicado: (2016)

Polymorphisms of Dopamine Receptor Genes and Risk of L-Dopa–Induced Dyskinesia in Parkinson’s Disease
por: Comi, Cristoforo, et al.
Publicado: (2017)

Dopamine D3 Receptor Plasticity in Parkinson’s Disease and L-DOPA-Induced Dyskinesia
por: Lanza, Kathryn, et al.
Publicado: (2021)

Basal ganglia neuropeptides show abnormal processing associated with L-DOPA-induced dyskinesia
por: Hulme, Heather, et al.
Publicado: (2022)

Phosphodiesterase 10A Inhibition Modulates the Corticostriatal Activity and L-DOPA-Induced Dyskinesia
por: Guimarães, Rayanne Poletti, et al.
Publicado: (2022)

7-Nitroindazole reduces L-DOPA-induced dyskinesias in non-human Parkinsonian primate
por: Herrero, M. T., et al.
Publicado: (2023)

Behavioral effects of zonisamide on L-DOPA-induced dyskinesia in Parkinson's disease model mice
por: Sano, Hiromi, et al.
Publicado: (2023)

An Integrative Approach to Treat Parkinson's Disease: Ukgansan Complements L-Dopa by Ameliorating Dopaminergic Neuronal Damage and L-Dopa-Induced Dyskinesia in Mice
por: Huh, Eugene, et al.
Publicado: (2019)

High-fat diet-induced diabetes leads to vascular alterations, pericyte reduction, and perivascular depletion of microglia in a 6-OHDA toxin model of Parkinson disease
por: Elabi, Osama F., et al.
Publicado: (2021)

A review of ropinirole prolonged release in Parkinson’s disease
por: Nashatizadeh, Muhammad M, et al.
Publicado: (2009)

Othello Syndrome Secondary to Ropinirole: A Case Study
por: Pal, Kakali, et al.
Publicado: (2012)

Nanotechnology-based drug delivery of ropinirole for Parkinson’s disease
por: Barcia, Emilia, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_rji94r2ma3glp6cbbfubh2rob7